Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-03-17. The firm is focused on developing and commercializing differentiated products in ophthalmology. The firm is focused on building its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on specialized therapeutic areas. Its products include ZIMED PF and PAUL GLAUCOMA IMPLANT. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease and is already available in over 40 countries around the world. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. The firm is also developing REV-0100, which is in preclinical development as a treatment for Stargardt disease.
Follow-Up Questions
Qui est le CEO de Aequus Pharmaceuticals Inc ?
Mr. Douglas Janzen est le Chairman of the Board de Aequus Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2013.
Quelle est la performance du prix de l'action AQSZF ?
Le prix actuel de AQSZF est de $0.0038, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Aequus Pharmaceuticals Inc ?
Aequus Pharmaceuticals Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Aequus Pharmaceuticals Inc ?
La capitalisation boursière actuelle de Aequus Pharmaceuticals Inc est de $510.6K
